Topic: Screening Libraries
Merck and HitGen upsized their licensing agreement to a full discovery collaboration, screening DNA-encoded libraries of billions of small molecules.
Chinese biotech NetVation DL Medicine has arrived on the scene with a two-year alliance with Pfizer, plus an equity investment from the big pharma group.
GSK and Warp Drive Bio are combining their drug discovery expertise in a bid to find small-molecule drugs to treat intractable disease targets.
Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.
Newly bought-out Actelion, which penned a $30 billion deal with Johnson & Johnson today, hasn't let that stop it from making its own deals earlier this week.